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The Impact of T Helper and T Regulatory Cells on
the Regulation of Anti-Double-Stranded DNA B Cells
HEL B cells that do not develop in the presence of
self-antigen) proliferated and secreted antibody when
provided with sHEL and T cell help (Cook et al., 1994,
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In studying B cell tolerance, we have focused on Bbe found in healthy individuals. In this study, we exam-
cells that are directed against a disease-associated anti-ined the potential of these anergic cells to become
gen, double-stranded DNA (dsDNA). Anti-dsDNA B cellsactivated. We show that anergy of anti-double-
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in the serum but also deposited in the diseased kidneyshelp. We further show that spontaneous loss of anergy
of SLE patients (Tan, 1989). We have previously docu-among anti-dsDNA B cells in autoimmune lpr/lpr mice
mented an anergic phenotype for anti-dsDNA B cells inoccurs in two phases: an abortive initial response to
BALB/c mice. Similar to anergic anti-HEL B cells, aner-T help followed by full loss of tolerance. Strikingly, the
gic anti-dsDNA B cells fail to secrete antibody, expressabortive response can be reproduced in nonautoim-
low levels of surface immunoglobulin (Ig), and, whenmune mice when CD4CD25 T regulatory cells are
surrounded by a diverse B cell repertoire, are excludedadministered in conjunction with CD4 T helper cells,
from the splenic B cell follicle (Mandik-Nayak et al.,suggesting that loss of B cell tolerance may require
1997). Also like anergic anti-HEL B cells, anergic anti-both the production of T cell help and the overcoming
dsDNA B cells have an increased turnover rate relativeof T suppression.
to nonautoreactive peripheral B cells (Mandik-Nayak et
al., 2000). However, anti-dsDNA B cells live twice as
Introduction long as anergic anti-HEL B cells (Mandik-Nayak et al.,
2000), and additional differences have been reported
Studies published over the past several years have doc- for these two types of anergic B cells. For example, anti-
umented a variety of ways in which autoreactive cells dsDNA B cells are unable to proliferate in response to
can be regulated, one of which is functional inactivation lipopolysaccharide, while anti-HEL B cells are readily
or anergy (reviewed in Goodnow, 1996). In this mecha- responsive (Goodnow et al., 1991; Mandik-Nayak et al.,
nism of tolerance, autoreactive cells are disabled so that 2000).
they cannot participate in an immune response. This In the present study, we demonstrate that, in contrast
tolerogenic pathway appears to present a substantial to anergic anti-HEL B cells, anergic anti-dsDNA B cells
risk to an individual. Given that the autoreactive cells can be activated simply by the provision of T cell help.
are still present in the host, it is conceivable that they Within 10 days of receiving T cell help, anti-dsDNA B
could be reactivated, leading to autoimmune disease. cells in BALB/c mice lose their anergic features and
To understand the extent of this danger, several secrete autoantibody. Strikingly, if T cell help becomes
groups have attempted to activate anergic B cells di- available in the presence of CD4CD25 T regulatory
rected against the model antigen hen-egg lysozyme cells, the anti-dsDNA B cells lose some of their anergic
(HEL). These cells are produced when anti-HEL B cells characteristics but remain unable to secrete autoanti-
develop in the presence of a soluble form of HEL (sHEL)
body. This abortive response closely resembles the ini-
(Goodnow et al., 1988). Naive anti-HEL B cells (i.e., anti-
tial stage of tolerance breakdown seen in autoimmune
lpr/lpr mice, which as we show here is also CD4 de-
pendent.5 Correspondence: jan@wistar.upenn.edu
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Figure 1. Provision of T Cell Help to Anti-dsDNA B Cells in BALB/c Mice
(A) In VH3H9/HACII BALB/c mice, Class II cells such as DCs and B cells express HA and present peptides processed from HA. VH3H9/HACII
mice were injected with 2  107 T cells directed against the S1 peptide of HA (TS1 T cells) as a source of cognate T cell help for the anti-
dsDNA B cells. Mice were sacrificed 10 days later, and the results were analyzed.
(B) Spleen sections were stained with antibodies against CD22 (brown) and Ig (blue). In uninjected VH3H9/HACII mice (left, n  5/5), Ig
anti-dsDNA B cells were excluded from the B cell follicle. However, after receiving TS1 T cells, anti-dsDNA B cells in VH3H9/HACII mice were
found within the B cell follicle (right, n  8/8). Additionally, darkly staining Ig anti-dsDNA AFCs were seen in the T cell area and at the bridging
channels to the red pulp.
(C) Spleen cells from TS1-injected mice were stained with antibodies against B220, CD22, and Ig. Histograms show B220 and CD22 staining
for either VH3H9/HACII (red lines) or VH3H9 alone (black lines) mice that received TS1 T cells. For ease of comparison, vertical lines are
included as static reference points for each marker. In VH3H9/HACII mice, both the Ig B cells (B220Ig cells) and the Ig anti-dsDNA
B cells (B220Ig cells) upregulated levels of B220 and CD22 (n  8/8). In contrast, the B cells in VH3H9 alone mice appeared unaffected
by exposure to TS1 T cells: the majority of Ig B cells expressed a mature phenotype, whereas the Ig anti-dsDNA B cells expressed lower
levels of B220 and CD22 (n  4/4).
Results II promoter (Jordan et al., 2001). In HACII mice, HA is
expressed on the surface of MHC class II cells, includ-
ing dendritic cells (DCs) and B cells, and peptides de-Model System for Providing Anti-dsDNA B Cells
with T Cell Help rived from HA are presented by MHC class II molecules.
Thus, anti-dsDNA B cells from VH3H9/HACII mice canTo study anti-dsDNA B cells, we have used the VH3H9
transgene (Tg). This Ig heavy chain Tg combines with interact with HA-specific CD4 T cells in a cognate fash-
ion. As a source of such T cells, we used the lymphendogenous light chains to form both anti-DNA and non-
autoreactive antibodies (Erikson et al., 1991; Ibrahim et nodes (LNs) of TS1 Tg mice, which express a T cell
receptor Tg directed against the major I-Ed-restrictedal., 1995; Roark et al., 1995). In particular, the pairing of
the VH3H9 Tg with the endogenous 1 light chain yields determinant of HA (designated S1) (Kirberg et al., 1994).
The expression of HA did not alter the phenotype oran anti-dsDNA antibody (Radic et al., 1991). Therefore,
anti-dsDNA B cells can be tracked in the diverse B cell fate of anti-dsDNA B cells based on several parameters.
As in VH3H9 BALB/c mice (Mandik-Nayak et al., 1997),repertoire of VH3H9 Tg mice by using -specific re-
agents. the anti-dsDNA B cells in VH3H9/HACII mice expressed
low levels of surface Ig in both the bone marrow (BM)Given the difficulties involved in identifying and isolat-
ing the bona fide T cells driving the anti-dsDNA re- and spleen, consistent with antigen encounter (data not
shown). This was accompanied by reduced expressionsponse, we used a model system to determine if BALB/c
anti-dsDNA B cells can be activated by T cell help (sche- of cell surface markers such as B220 and CD22 (data
not shown); given that levels of these markers increasematized in Figure 1A). For this, we mated VH3H9 BALB/c
mice with HACII BALB/c mice, which express influenza with B cell maturation (Hardy et al., 1991; Nitschke et al.,
1997), we have suggested that encounter with antigen inhemagglutinin (HA) under the control of the MHC class
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Table 1. Anti-dsDNA Antibody Titers in TS1-Injected Mice
VH3H9 VH3H9/HACII HACII
(n  4) (n  8) (n  7)
pre-TS1 10 10 10
post-TS1 10 7.50 102  3.18 102 5.18  102  4.39  102
Serum samples were taken from VH3H9, VH3H9/HACII, and HACII mice immediately before treatment (pre-TS1) and ten days after receiving
2 107 TS1 LN cells (post-TS1). Anti-dsDNA antibody titers were detected using the C. luciliae assay as described in Experimental Procedures.
Note that for VH3H9 and VH3H9/HACII mice, mean Ig anti-dsDNA antibody titers are indicated, whereas for HACII mice, mean total anti-
dsDNA antibody titers are shown.
the BM causes the anti-dsDNA B cells to halt in develop- anti-dsDNA B cells that are similar to the Ig anti-dsDNA
B cells in VH3H9 Tg mice. If given T cell help, anti-dsDNAment (Mandik-Nayak et al., 1997, 1999). By immunohis-
tochemistry, the anti-dsDNA B cells were excluded from B cells from either VH3H9 or Tg() mice can become
activated to secrete autoantibodies, consistent with ear-the splenic B cell follicle, localizing instead to the T/B
interface (Figure 1B). Finally, anti-dsDNA antibody was lier studies showing that allo-T help generated SLE-like
autoantibodies (Gleichmann et al., 1984; Morris et al.,not detected in the serum of VH3H9/HACII mice, veri-
fying that anergy is maintained (Table 1). By all these 1990).
measures, the anti-dsDNA B cells in VH3H9/HACII mice
are indistinguishable from those in BALB/c mice that T Cell Help Breaks Anergy of Splenic
express only the VH3H9 Tg. Anti-dsDNA B Cells
There are multiple sites at which T cell help could act
to disrupt tolerance of anti-dsDNA B cells. T cell helpBALB/c Anti-dsDNA B Cells Can Be Activated
by T Cell Help might block the initial induction of anergy in the BM;
alternatively, it could act in the periphery to reverse theStrikingly, 10 days after receiving 2  107 TS1 LN cells,
eight out of eight VH3H9/HACII mice exhibited serum Ig anergic state. To test the latter possibility, splenic anti-
dsDNA B cells were transferred to a third party mouseanti-dsDNA antibodies (Table 1). Immunohistochemical
analysis of the spleens of these mice revealed that in- and given T cell help (outlined in Figure 2A). CB17 mice,
which are identical to BALB/c mice except for their Igstead of lining up at the T/B interface, VH3H9/Ig anti-
dsDNA B cells could now be found in the B cell follicle heavy chain allotype, were used as recipients. Trans-
ferred Ig anti-dsDNA B cells (IgMa) could thus be distin-(Figure 1B). Additionally, and consistent with the pres-
ence of anti-dsDNA antibodies in the serum, darkly guished from the endogenous CB17 B cells (IgMb) with
IgMa-specific reagents. The CB17 mice were first in-staining Ig cells appeared in the T cell area, at the
bridging channels to the red pulp and in the red pulp, jected with a mixture of 2 107 TS1 LN cells and nonin-
fectious influenza virus. After allowing 1 day for the TS1and staining with syndecan-1 (Smith et al., 1996) con-
firmed that these cells are antibody-forming cells (AFCs) T cells to be activated by antigen, HACII anti-dsDNA B
cells were transferred into the mice. As a highly enriched(Figure 1B and data not shown). The unusual localization
of AFCs in the T cell area is similar to that which has source of these anti-dsDNA B cells, we used VH3H9/
HACII mice that were deficient in the Ig locus (VH3H9/been previously reported for autoimmune responses in
MRL-lpr/lpr mice (Jacobson et al., 1995; Mandik-Nayak HACII// BALB/c mice). In the absence of Ig B cells,
the majority of the B cells in VH3H9// BALB/c miceet al., 1999). Finally, by flow cytometry all the B cells,
including the Ig anti-dsDNA B cells, expressed higher (	85%) are Ig1 anti-dsDNA B cells that are phenotypi-
cally indistinguishable from Ig1 anti-dsDNA B cells inlevels of B220 and CD22 (Figure 1C). Since all the B cells
express the HACII Tg and can interact with TS1 T cells, VH3H9 BALB/c mice (A. Eaton-Bassiri and J.E., unpub-
lished data).it is perhaps not surprising that most of the B cells would
exhibit some alterations. Thus, in contrast to anergic Three days later, the anti-dsDNA B cells expressed
increased levels of B220 and CD22, suggesting that theyanti-HEL B cells, anergic anti-dsDNA B cells are able to
respond to T cell help and are not eliminated by it in were maturing in response to T cell help. In contrast,
anti-dsDNA B cells transferred without T cell help dida Fas-dependent manner. Indeed, similar experiments
using Fas ligand-deficient (gld/gld) TS1 T cells to provide not upregulate B220 or CD22. (Figure 2B). By immuno-
histochemistry, the anti-dsDNA B cells given T cell helpT cell help yielded indistinguishable results (n  4, data
not shown), suggesting that the Fas/FasL pathway may were found throughout the white pulp, localizing within
both the PALS and the B cell follicle (Figure 2C, n  4).have very little effect on the response of anti-dsDNA
B cells to T cell help. AFCs were not apparent at this time point, and serum
anti-dsDNA antibodies were not detectable (n  10).No changes in terms of localization, cell surface phe-
notype, or antibody secretion were apparent in anti- On day 7, the anti-dsDNA B cells continued to express
increased levels of B220 and CD22 relative to anti-dsDNA B cells when VH3H9 mice lacking the HACII Tg
were given TS1 cells (Figure 1C, Table 1, and data not dsDNA B cells which did not receive T cell help (n  4,
data not shown). In addition, many anti-dsDNA AFCsshown). Notably, however, serum anti-dsDNA antibod-
ies were found when TS1 T cells were injected into HACII were evident in the spleen (Figure 2D, n  4), and Ig
anti-dsDNA antibodies were found in the serum of allmice that did not express the VH3H9 Tg (Table 1). These
data suggest that the normal B cell repertoire contains mice examined (n  8, mean titer  1.78  102 ). On day
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Figure 2. T Cell Help for Splenic Anti-dsDNA B Cells
(A) CB17 mice (IgMb) were injected with 2  107 CFSE-labeled TS1 T cells and noninfectious influenza virus and, 1 day later, given 1.0–1.5 
107 splenic HA-expressing Ig anti-dsDNA B cells (IgMa). As a highly enriched source of Ig anti-dsDNA B cells, mice deficient at the Ig locus
(VH3H9/HACII// mice) were used.
(B) Three days after injection with anti-dsDNA B cells, mice were sacrificed and spleen cells were stained with antibodies against IgMa and
either B220 or CD22. Black histograms in both panels show the levels of these markers on unmanipulated anti-dsDNA B cells (CFSEIgMa
cells from VH3H9// mice). Overlaid histograms show levels of B220 and CD22 on transferred anti-dsDNA B cells (CFSEIgMa cells). Anti-
dsDNA B cells that received T help (red histograms, n  4/4) expressed higher levels of B220 and CD22 relative to unmanipulated anti-dsDNA
B cells or anti-dsDNA B cells transferred in the absence of T help (blue histograms, n  3/3).
(C) Spleen sections from mice 3 days postinjection with anti-dsDNA B cells were stained with antibodies against IgMa (brown) and either
CD22 (blue, left) or CD4 (blue, right). At this time point, anti-dsDNA B cells given T cell help localized in both the PALS and the B cell follicle
(n  4/4).
(D) Seven (left) and ten days (right) after transfer of anti-dsDNA B cells, spleen sections were stained with antibodies against IgMa (blue) and
CD22 (brown). In the presence of T cell help, anti-dsDNA AFCs were prominent at day 7 (n 4/4) and persisted at day 10 (n  3/3). In contrast,
when anti-dsDNA B cells were transferred in the absence of T help (n  3/3, data not shown), few to no cells were detected by flow cytometry
or immunohistochemistry.
10, using antibodies against surface Ig and B220, the cells may see T cell help only once they have reached
the spleen. We would predict that, like the splenic anti-anti-dsDNA B cells were undetectable by flow cytometry
(data not shown). However, by immunohistochemistry, dsDNA B cells in the transfer experiments, these B cells
would form AFCs at the bridging zones. However, otheranti-dsDNA B cells could still be seen in these mice;
most, if not all, appeared to be terminally differentiated anti-dsDNA B cells may receive T cell help in the BM
shortly after antigen encounter and form AFCs in theAFCs (Figure 2D, n 3). Since AFCs have been reported
to lose surface expression of Ig and B220 (Smith et al., PALS. This issue could be investigated by administering
T cell help to BM anti-dsDNA B cells.1996), this may explain the failure to detect these cells
by flow cytometry. These data demonstrate that anergic anti-dsDNA B
cells from the spleen can be reactivated by cognate TIt is interesting to note that the localization of the
AFCs in this experiment was strikingly uniform, with cell help. AFC formation and autoantibody secretion is
quickly detected, with kinetics similar to that reportedAFCs appearing almost exclusively at the bridging chan-
nels to the red pulp (Figure 2D). In contrast, when T cell for responses to exogenous antigens (Garside et al.,
1998; Jacob et al., 1991; Smith et al., 1996). We havehelp was administered to intact VH3H9/HACII mice
rather than to transferred spleen cells, AFCs also ap- also found this to be true for anergic anti-dsDNA B cells
from the LN (A. Eaton-Bassiri and J.E., unpublishedpeared in the PALS (Figure 1B). One possibility is that
in the intact mouse, there is less synchronicity in the data). Together, these data show that cognate T cell
help can reverse anergy of anti-dsDNA B cells.anti-dsDNA B cell population with respect to the timing
of T cell help relative to antigen encounter. For example, We tested whether simply being exposed to activated
T cells rather than participating in a cognate T/B interac-after antigen encounter in the BM, some anti-dsDNA B
T Help and T Suppression of Anti-dsDNA B Cells
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Figure 3. Anti-CD4 Treatment of lpr/lpr Mice
VH3H9 MRL-lpr/lpr (n  5/5) and VH3H9 BALB-lpr/lpr (n  3/3) mice were treated with anti-CD4 antibody.
(A) Spleen sections from control-injected (top) and anti-CD4-treated (bottom) mice were stained with antibodies against CD22 (brown) and
Ig (blue). While anti-dsDNA B cells are normally found in the B cell follicles of lpr/lpr mice, after anti-CD4 treatment they primarily localized
to the T/B interface.
(B) Spleen cells from anti-CD4-treated lpr/lpr mice were stained with antibodies against CD19, Ig, and either B220 or CD22. VH3H9 MRL-
lpr/lpr and VH3H9 BALB-lpr/lpr mice gave indistinguishable results. Gated on CD19Ig cells, histograms show that levels of B220 and CD22
were lower on anti-dsDNA B cells from anti-CD4-treated lpr/lpr mice (red line) than on anti-dsDNA B cells from PBS-injected lpr/lpr mice
(black line, n  6/6).
(C) Spleen cells from Tg() (n  3/3) or VH3H9 BALB/c mice (n  6/6) were stained for CXCR5 expression as described in the Experimental
Procedures. CXCR5 levels on Ig B cells (CD19Ig cells, red lines) are overlaid CXCR5 levels on Ig B cells (CD19Ig cells, black lines).
For ease of comparison, vertical lines are included as a static reference point. Compared to the surrounding Ig B cells and to B cells from
Tg() mice, VH3H9/Ig anti-dsDNA B cells expressed 30%–57% lower levels of CXCR5. Consistent with this (D), they exhibited impaired
migration in response to CXCL13 (BLC).
(E) Spleen cells from VH3H9 MRL-lpr/lpr mice were stained for CXCR5 expression. Normally (left, n  9/9), CXCR5 levels on lpr/lpr Ig anti-
dsDNA B cells (red lines) are comparable to those on the rest of the B cells in the mouse (black lines). Following anti-CD4 treatment, however,
they expressed 39%–54% lower levels of CXCR5 than the surrounding B cells (n  3/3).
tion could also rescue anergic anti-dsDNA B cells. First, cells were recovered. This recovery was significantly
less (p 0.0159) than that seen when cognate help was2  107 TS1 LN cells were injected into CB17 mice
that expressed the HACII Tg. After allowing 1 day for provided to spleen anti-dsDNA B cells (31.38  9.53%,
n  4). Additionally, IgMa anti-dsDNA antibodies re-activation of the T cells, Ig anti-dsDNA B cells that did
not express HA were transferred into this environment to mained undetectable in the serum. Not surprisingly,
however, non-IgMa anti-dsDNA antibodies were appar-receive bystander stimulation. Seven days posttransfer,
only 4.32  0.54% (n  5) of the donor anti-dsDNA B ent in the serum of all five experimental mice (data not
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are evident in the spleen. Previous studies in MRL-lpr/
lpr mice (Chesnutt et al., 1998; Jabs et al., 1992; Koh et
al., 1995; Merino et al., 1993; Santoro et al., 1988) sug-
gest that this terminal differentiation of anti-dsDNA
B cells occurs in response to CD4 T cell help. Notably,
however, even before this clear break in tolerance, the
lpr/lpr anti-dsDNA B cells are altered relative to anergic
BALB/c anti-dsDNA B cells. Instead of halting in devel-
opment and accumulating at the T/B interface, the anti-
dsDNA B cells in young lpr/lpr mice are able to mature
and enter the B cell follicle (Fields et al., 2001; Mandik-
Nayak et al., 1999). Thus, in these mice, anti-dsDNA
B cell anergy is lost in a step-wise fashion.
To determine the role of T cell help in the initial stage
of tolerance loss in lpr/lpr mice, anti-CD4 antibody was
administered to 5- to 6-week-old VH3H9 MRL-lpr/lpr
and VH3H9 BALB-lpr/lpr mice. The VH3H9 lpr/lpr mice
were injected with anti-CD4 antibody once a week for
two weeks and then sacrificed. Given that the turnover
rate of anti-dsDNA B cells in the spleens of MRL-lpr/lpr
and BALB-lpr/lpr mice is accelerated relative to non-
anti-dsDNA B cells (Mandik-Nayak et al., 2000 and pre-
liminary data), the majority of the cells evaluated will
have developed during the course of anti-CD4 treat-
ment. Flow cytometric analysis at the end of treatment
revealed that the number of CD4 T cells in the spleen
was decreased by 83%–93% when compared to mice
injected with control rat antibody or PBS (data not
shown).
Anti-CD4 treatment dramatically affected the localiza-
tion of the lpr/lpr anti-dsDNA B cells. In PBS-injected
or control antibody-injected lpr/lpr mice, the VH3H9/Ig
Figure 4. Costimulatory Blockade of MRL-lpr/lpr Mice
anti-dsDNA B cells populated the B cell follicles. After
VH3H9 MRL-lpr/lpr mice were treated with either MR1 (anti-CD40L,
anti-CD4 treatment, however, they primarily localized ton  3/3) or CTLA4Ig (n  3/3).
the T/B interface (Figure 3A). Additionally, after anti-(A) Spleen sections were stained with antibodies against CD22
CD4 treatment, the anti-dsDNA B cells in lpr/lpr mice(brown) and Ig (blue). Anti-dsDNA B cells in VH3H9 MRL-lpr/lpr
mice were follicularly excluded after anti-CD40L treatment; in con- expressed lower levels of B220 and CD22 (Figure 3B),
trast, they remained in the follicle of CTLA4Ig-treated mice. suggesting that in the absence of CD4 T cells, the anti-
(B) Spleen cells were stained with antibodies against CD3, CD8, dsDNA B cells halt in development. Thus, the first step
B220, and the T cell activation marker CD69. Histograms show CD69
in the loss of anergy in lpr/lpr mice—maturation andstaining on CD4 T cells (defined as CD3CD8B220 lymphocytes).
follicular entry of the anti-dsDNA B cells—appears toIn both anti-CD40L- and CTLA4Ig-treated lpr/lpr mice, the percent-
reflect an abortive response to T cell help.age of CD4 T cells expressing CD69 was reduced compared to
control (n  5/5) lpr/lpr mice (p  0.0073 and p  0.0133, respec-
tively). CXCR5 Expression Correlates with Splenic
Localization of Anti-dsDNA B Cells
Expression of the chemokine receptor CXCR5 has been
shown). We presume that these arose from the endoge- shown to correlate with both the ability to migrate into
nous anti-dsDNA B cells of the CB17-HACII recipient B cell follicles and with B cell maturation (Cyster et al.,
mouse, which had been activated by cognate interaction 1999). Given that the Ig anti-dsDNA B cells in VH3H9
with TS1 T cells. Thus, in contrast to cognate T/B interac- BALB/c mice are excluded from the B cell follicle and
tion, bystander stimulation appeared inefficient at acti- appear immature, they might be expected to express
vating anti-dsDNA B cells. low levels of CXCR5. Indeed, by flow cytometry, the Ig
anti-dsDNA B cells expressed 30%–57% lower levels
of CXCR5 than either the rest of the B cells in the mouseActivation of Anti-dsDNA B Cells in lpr/lpr Mice
Having shown that exogenous T cell help can activate or IgB cells in Tg() BALB/c mice (Figure 3C). Addition-
ally, when compared to either of these two groups, theyanergic B cells in nonautoimmune mice, we next exam-
ined how anergy of anti-dsDNA B cells is actually lost exhibited impaired migration to the chemokine CXCL13
(BLC), which signals through the CXCR5 receptor (Fig-in an autoimmune context. We have previously reported
that Ig anti-dsDNA B cells become spontaneously acti- ure 3D and data not shown) (Gunn et al., 1998).
CXCR5 expression was also analyzed on MRL-lpr/lprvated in MRL-lpr/lpr and BALB-lpr/lpr mice (Fields et
al., 2001; Mandik-Nayak et al., 1999). By 10 to 12 weeks anti-dsDNA B cells before and after anti-CD4 treatment.
Consistent with their maturity and with their follicularof age, Ig anti-dsDNA antibodies become detectable
in the serum of lpr/lpr mice, and Ig anti-dsDNA AFCs localization, Ig anti-dsDNA B cells from unmanipulated
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Figure 5. The Impact of T Regulatory Cells on Activation of Anti-dsDNA B Cells
VH3H9/HACII mice were injected with a combination of 2 106 T helper cells (CD4CD25 cells) sorted from TS1 mice and 2 106 T regulatory
cells (CD4CD25 cells) sorted from TS1xHA28 mice. Ten days later, the mice were sacrificed.
(A) Spleen cells were stained with antibodies against Ig, B220, and CD22. Black lines in all panels show levels of B220 and CD22 on anti-
dsDNA B cells (B220Ig cells) from unmanipulated VH3H9 mice (n  5/5). Anti-dsDNA B cells in VH3H9/HACII mice that received a
combination of sorted T helper cells and T regulatory cells (blue lines, n  3/3) did not upregulate B220 and CD22 to the same extent as
when sorted T helper cells alone were injected (red lines, n  3/3).
(B) Spleen sections were stained with antibodies against CD22 (brown) and Ig (blue). Each column consists of pictures of two separate mice
from the same treatment group. Anti-dsDNA B cells were largely excluded from the B cell follicle when no T help was given (left, n  5/5
mice). When given sorted T helper cells (middle, n  3/3 mice), anti-dsDNA B cells moved into the follicle and AFC formation was observed.
In VH3H9/HACII mice which received a combination of sorted T helper cells and T regulatory cells (right, n  3/3), Ig anti-dsDNA B cells
became able to move into the follicle. Strikingly, however, there was little to no evidence of AFC formation.
or control-injected VH3H9 MRL-lpr/lpr mice expressed B cells, 5-week-old VH3H9 MRL-lpr/lpr mice were
treated for 2 weeks with either anti-CD40L antibody orlevels of CXCR5 equivalent to the other B cells in the
mice (Figure 3E). In contrast, and correlating with their CTLA4Ig (which blocks both B7-CD28 and B7-CTLA4
interactions). In anti-CD40L-treated MRL-lpr/lpr mice,immaturity and follicular exclusion, Ig anti-dsDNA
B cells from anti-CD4-treated VH3H9 MRL-lpr/lpr mice the anti-dsDNA B cells were immature (data not shown)
and excluded from the B cell follicle (Figure 4A), similarexpressed 39%–54% lower levels of CXCR5 than the
rest of the B cell population. to what we observed with anti-CD4 treatment (Figures
3A and 3B). In contrast, the anti-dsDNA B cells in
CTLA4Ig-treated mice appeared indistinguishable fromBlockade of CD40-CD40L but Not B7-CD28/CTLA4
those in MRL-lpr/lpr mice injected with control antibody.Results in the Follicular Exclusion and Developmental
These different outcomes occurred even though bothArrest of lpr/lpr Anti-dsDNA B Cells
treatments similarly affected the activation of T cells inThe requirement for CD40-CD40L or B7-CD28 interac-
MRL-lpr/lpr mice (Figure 4B). Consistent with previoustions in MRL-lpr/lpr autoantibody production has been
reports that a large proportion of the CD4 T cells incontroversial. The degree to which the absence of these
MRL-lpr/lpr mice exhibit an activated phenotype (Chancostimulatory signals affects autoantibody levels varies
and Shlomchik, 1998; Chan et al., 1999; Giese and David-from study to study (Kinoshita et al., 2000; Liang et al.,
son, 1992), 21%–36% of the CD4 T cells in control mice1999, 2000; Ma et al., 1996; Russell et al., 1998; Tada
expressed the activation marker CD69. After treatmentet al., 1999; Takiguchi et al., 1999). To evaluate the ef-
fects of these secondary interactions on anti-dsDNA with either anti-CD40L antibody or CTLA4Ig, however,
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there was a significant decrease in the percentage of gest that the spontaneous development of autoimmu-
nity may be a 2-fold process involving both the produc-activated (CD69) CD4 T cells. Thus, while disruption of
tion of activating factors like T cell help as well as theeither CD40-CD40L or B7-CD28/CTLA4 reduces T cell
surmounting of inhibitory factors such as T regulatoryactivation, only the blockade of CD40-CD40L signaling
cells.inhibits the follicular entry of anti-dsDNA B cells.
Anti-dsDNA B Cells Follow a Two-SignalThe Impact of CD4CD25 T Regulatory Cells
Model of Activationon the Activation of Anti-dsDNA B Cells
Considering that anti-dsDNA B cells become activatedGiven that the anti-dsDNA B cells in young lpr/lpr mice
if they are provided with T cell help, it appears thatappear to receive T cell help, it is striking that they fail
they very closely follow a two-signal model of activationto form AFCs and are only able to mature and enter the
(Bretscher and Cohn, 1970). The anti-dsDNA B cells seefollicle in response to this stimulus. In attempting to
their antigen in the BM (signal 1) and, if provided withunderstand what might cause this type of abortive B cell
T cell help (signal 2), are activated to produce antibody.response, we examined the impact of CD4CD25 T
This occurs even if signal 2 is delayed and T cell helpregulatory cells on the activation of anti-dsDNA B cells.
is provided to peripheral anti-dsDNA B cells. However,For this purpose, CD4CD25 T regulatory cells were
if the anti-dsDNA B cells do not receive T cell help (i.e.,sorted from TS1xHA28 mice, which have been shown
they receive signal 1 without signal 2), an overall tolerantto contain a distinct population of these cells (Jordan
state like that seen in BALB/c mice ensues.et al., 2001). T helper cells (CD4CD25) were similarly
As opposed to anti-dsDNA B cells, anergic anti-HELpurified from TS1 mice.
B cells cannot be activated to secrete antibody by theTransfer of 2  106 sorted T helper cells into VH3H9/
simple provision of T cell help. The contrasting re-HACII mice elicited a full response from the anti-dsDNA
sponses of these two types of B cells might be a directB cells which was indistinguishable from that seen when
consequence of the unique features of the antigens be-2  107 unsorted TS1 LN cells were used to provide T
ing recognized. It has been clearly shown that the qualityhelp (Figure 5). The additional transfer of 2  106 sorted
of signal delivered through the B cell receptor complexT regulatory cells significantly altered this response. Ten
could significantly impact the ability of a B cell to re-days after receiving a mixture of T regulatory and T
spond to T cell help. For example, in vitro studies havehelper cells, the Ig anti-dsDNA B cells did express
shown that anergic anti-HEL B cells, while sensitive toincreased levels of B220 and CD22 (Figure 5A). However,
Fas-mediated death in the presence of soluble HEL,the upregulation was more moderate than that seen
become resistant to Fas-mediated death if surface Igwhen T cell help alone was provided. In the latter case,
receptors are highly crosslinked (Foote et al., 1998).B220 and CD22 expression on the anti-dsDNA B cells
Additionally, in vivo modifications to the antigenic mi-becomes dramatically higher than that seen on mature,
lieu—either by elimination of antigen or by use of highlyfollicular B cells (Figures 1C and 5A). In contrast, and
crosslinking antigen—can allow anergic anti-HEL B cellssimilar to what is seen in lpr/lpr mice, anti-dsDNA B cells
to become responsive to T cell help (Cooke et al., 1994;that received both T helper cells and T regulatory cells
Goodnow et al., 1991). These results suggest that inexpressed levels of B220 and CD22 that were more
autoreactive B cell activation the mere presence of sig-comparable to those seen on follicular B cells (Figure
nal 2 is not the only critical parameter. The ability of the5A). Additionally, although many of the anti-dsDNA
B cell to respond to signal 2 may be dictated by theB cells now populated the B cell follicle (Figure 5B),
quality of signal 1.
there was little to no evidence of AFC formation, and
Given this, it is possible that anti-dsDNA B cells are
anti-dsDNA antibodies remained undetectable in the se-
resistant to Fas-mediated killing because highly cross-
rum. Thus, in the presence of T regulatory cells, the anti- linking forms of self-antigen are available to them, and
dsDNA B cells mounted an abortive response to T cell this leaves them open to receiving T cell help. Consistent
help that was strikingly similar to that seen in young lpr/ with this idea, it has been shown that, in addition to
lpr mice. being present in soluble forms (Rumore and Steinman,
1990), many of the nuclear antigens targeted in SLE
Discussion aggregate within distinct structures on the surface of
apoptotic cells (Casciola-Rosen et al., 1994). This sug-
In the present study, we investigated the requirements gests a novel explanation for why only a discrete set of
for activation of anti-dsDNA B cells. We found that, in autoantibodies arises in SLE. Compared to other anti-
stark contrast to anergic anti-HEL B cells, anergic anti- gens, nuclear antigens in particular may be available in
dsDNA B cells can be activated by the simple provision forms that are highly crosslinking. Therefore, when T cell
of T cell help. Within 10 days of receiving T cell help, tolerance lapses, anti-nuclear B cells are uniquely able
anergic anti-dsDNA B cells are able to mature, enter the to respond and produce the autoantibody spectrum
B cell follicle, and form AFCs. Furthermore, looking in seen in SLE. A complete test of this theory awaits a
lpr/lpr mice, we examined how anti-dsDNA B cells be- better understanding of the nature of the in vivo antigen
come activated in an autoimmune context. In this case, recognized by anti-dsDNA B cells.
it appears that the anti-dsDNA B cells initially experience
an abortive response to T cell help, maturing and enter- Fas May Regulate Tolerance to dsDNA
ing the B cell follicle but not differentiating into AFCs. by Controlling the Availability
Strikingly, the presence of CD4CD25 T regulatory of T Cell Help
cells causes a similarly abortive response in BALB/c Since Fas on the surface of anti-dsDNA B cells does
not prevent a response to T cell help but the absenceanti-dsDNA B cells. Taken together, these results sug-
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Figure 6. Model for the Impact of T Helper
and T Regulatory Cells on Autoreactive B
Cells
Splenic white pulp follicles are depicted with
the B cell area (gray) surrounding the T cell
area (white, with central arteriole []).
(A) Autoreactive B cells () localize to the T/B
interface in nonautoimmune-prone individu-
als as a result of antigen encounter in the
absence of T cell help. If T cell help is pro-
vided, the autoreactive B cells lose their aner-
gic characteristics and secrete autoantibody.
(B) CD4 CD25 T regulatory cells can limit
the response of autoreactive B cells to T cell
help, leading to a phenotype strikingly similar
to that seen for anti-dsDNA B cells in young
lpr/lpr mice. The eventual emergence of full-
blown autoimmunity reflects a shift to favor
T cell help over T suppression.
of Fas leads to anti-dsDNA antibodies, it appears likely prone individuals, developing autoreactive B cells en-
that Fas regulates B cell tolerance by controlling T cell counter their antigen but lack T help. In an autoimmune
help. This raises the question of why T cell help becomes context, T cell help becomes available, but the concomi-
available in lpr/lpr mice. Is this the primary result of Fas tant generation of T regulatory cells allows tolerance to
deficiency in the T cells themselves, or is it secondary be (at least initially) maintained: the autoreactive B cells
to some other defect in Fas-deficient mice? In the first exhibit some response to the T cell help, but they fail
case, T cell help arises from the survival of autoreactive to secrete autoantibodies. Finally, either a decline in T
T cells that would normally be eliminated via Fas signal- regulatory cell function or an increase in T cell help that
ing. While we do not dismiss this possibility, there are cannot be fully suppressed results in overt autoimmu-
several studies that argue against it. Most significantly, nity. In support of this idea, it has been demonstrated
Fas expression has been selectively restored on T cells that T suppressor cell function in patients with active
in MRL-lpr/lpr mice without a noticeable decrease in SLE is reduced compared to that seen in either healthy
autoantibody production (Fukuyama et al., 1998). An subjects or in SLE patients in remission (Filaci et al.,
alternate scenario, then, is that the activation of autore- 2001; Linker-Israeli et al., 1990). To further examine this
active T cells in lpr/lpr mice is a secondary effect due, issue, we are investigating the status of T regulatory
for example, to a disturbance in a cell type that is critical cells in lpr/lpr mice. The knowledge of how T regulatory
for T cell activation. In this regard, DCs express Fas cells are generated and how their function is controlled
(Matsue et al., 1999; Rescigno et al., 2000; Winzler et could lead to new therapeutic strategies for SLE.
al., 1997), and we have documented several unique attri-
butes of the DCs in lpr/lpr mice, including an abnormal Experimental Procedures
localization relative to their state of activation (Fields et
Miceal., 2001).
VH3H9 mice have been previously described (Erikson et al., 1991).
The VH3H9 Tg has been backcrossed onto the BALB/c, MRL-lpr/lpr,
The Influence of CD4CD25 T Regulatory Cells and BALB-lpr/lpr backgrounds for at least 17, 24, and 7 generations,
on Anti-dsDNA B Cells respectively. All VH3H9 mice were bred and maintained under spe-
Given that anti-dsDNA B cells in young lpr/lpr mice ap- cific-pathogen-free conditions at The Wistar Institute. TS1 Tg
BALB/c mice (Kirberg et al., 1994), HA28 Tg BALB/c mice (Cerasolipear to have received T cell help, the absence of AFCs
et al., 1995; Shih et al., 1997), HACII Tg CB17 mice, and HACII Tgin these mice is intriguing. It is particularly notable given
BALB/c mice (Jordan et al., 2001) were bred and maintained in athat we were able to detect anti-dsDNA B cell matura-
separate specific-pathogen-free room at The Wistar Institute. /
tion, follicular entry, and antibody secretion after only BALB/c mice (Chen et al., 1993) were obtained from M. Weigert
10 days when T cell help was administered to BALB/c (Princeton University, Princeton, NJ). To detect the presence of the
mice. In an attempt to recapitulate the phenotype of anti- VH3H9, TS1, and HA Tgs, PCR amplification of tail DNA was carried
out as described (Cerasoli et al., 1995; Erikson et al., 1991; KirbergdsDNA B cells in young lpr/lpr mice, we administered a
et al., 1994). Deficiency in the Ig locus was determined by flowmixture of CD4CD25 T regulatory cells and nonaner-
cytometry of peripheral blood lymphocytes, looking for the absencegic T cell help to BALB/c anti-dsDNA B cells. This re-
of Ig B cells. CB17 mice were purchased from Taconic (German-sulted in an abortive response by the anti-dsDNA B cells
town, NY).
that was strikingly similar to what we have documented
in young lpr/lpr mice. TS1 T Cell and PR8 Virus Injections
While there has been one report that T regulatory Single-cell suspensions were prepared from the cervical, mandibu-
cells can influence T cell-mediated autoimmunity in NOD lar, axillary, brachial, and inguinal LNs of TS1 Tg mice or TS1xHA28
mice as noted in the text. When unsorted LN cells were used, theymice (Salomon et al., 2000), very little is known about
were labeled with CFSE (Molecular Probes, Eugene, OR) as de-the role of T regulatory cells in inhibiting autoantibody
scribed (Wells et al., 1997), and 2  107 cells were intravenouslyresponses. Our data suggest that they could play a cru-
injected into recipient mice. For sorting experiments, cells were
cial role in downmodulating the response of autoreactive stained with 7D4-FITC (anti-CD25) and GK1.5-PE (anti-CD4) (both
B cells in the event that T help becomes available. As purchased from BD PharMingen, San Diego, CA) and sorted on a
one model for the evolution of autoimmunity, we would Cytomation MoFlo; purity was 
96% in all sorts (data not shown).
Subsequently, 2 106 sorted CD4CD25 cells from TS1 mice weresuggest the following (Figure 6). In nonautoimmune-
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injected either alone or in combination with 2  106 sorted signal amplification. Anti-FITC-horseradish peroxidase (HRP)
(Chemicon, Temecula, CA), anti-FITC-AP (Sigma), and streptavidin-CD4CD25 cells from TS1xHA28 mice.
In some experiments, noninfectious influenza PR8 virus (prepared HRP (Southern Biotechnology Associates) were used as secondary
antibodies. Analysis of histological samples was performed by atas described [Reed et al., 2000]) was used to provide antigenic
stimulation to the TS1 T cells. In all cases, 103 hemagglutinating least three independent, blinded observers. For all figures, pictures
shown are representative of all the mice examined in a particularunits (determined as described [Fazekas de St. Groth and Webster,
1966]) were injected intravenously in PBS. experimental group.
Detection of Anti-dsDNA AntibodiesAnti-dsDNA B Cell Transfers
The presence of anti-dsDNA antibodies in serum was detected usingSpleen cell suspensions were prepared from VH3H9/HACII//
fixed, permeabilized Crithidia luciliae (Aarden et al., 1975) as themice or VH3H9// mice as indicated in the text. Flow cytometry
substrate (Antibodies Incorporated, Davis, CA). In this work, anti-was used to determine the frequency of Ig anti-dsDNA B cells, and
dsDNA antibody was said to be undetectable in the serum if norecipient mice were intravenously injected with spleen preparations
staining of the kinetoplast (which indicates the presence of anti-containing 1–1.5  107 anti-dsDNA B cells.
dsDNA antibody) was seen at a 1:100 dilution. The presence of
total anti-dsDNA antibody was measured by initially testing serumAnti-CD4 Treatment
samples at a 1:100 dilution and detecting staining of the kinetoplastIn all cases, mice were 5–6 weeks old at the beginning of treatment.
with a combination of FITC-conjugated goat anti-mouse IgG andMice were intravenously injected with 0.9 or 1.0 mg of GK1.5 (rat
anti-mouse IgM reagents (Southern Biotechnology Associates). Theanti-CD4) on days 0 and 7 and sacrificed on day 14. Initially, control
samples were visualized under a fluorescent microscope and scoredmice were injected with J1.2, a control rat IgG2b antibody. While
blindly. When anti-dsDNA antibody was detected, samples werethese immunizations did not change the localization of anti-dsDNA
also tested at serial 10-fold dilutions from 1:100 to 1:10,000. TheB cells (data not shown), they did result in abundant germinal center
serum titer was defined as the reciprocal of the last dilution at whichformation that distorted the follicular architecture; no such immune
kinetoplast staining was seen. Serum samples were also specificallyresponse was detected in anti-CD4-treated mice. Therefore, in sub-
tested for Ig anti-dsDNA antibody titers at serial 10-fold dilutionssequent experiments, uninjected mice and mice injected with sterile
from 1:100 to 1:10,000. In the context of the VH3H9 Tg, only thePBS were used as controls.
germline 1 light chain out of the  light chains scores positive in
this assay; therefore, the secondary reagent for these titers was aCostimulatory Blockade
FITC-conjugated polyclonal goat anti-mouse Ig antibody (SouthernIn all cases, 5-week-old VH3H9 MRL-lpr/lpr mice were used. For
Biotechnology Associates). In transfer experiments into CB17 mice,anti-CD40L treatment, mice were intraperitoneally injected with 250
IgMa anti-dsDNA antibody titers were also measured using DS-1-g of MR1 (R. Noelle, Dartmouth Medical School, Lebanon, NH) on
FITC (anti-IgMa, BD PharMingen).days 0, 4, 7, and 10 and sacrificed on day 14. For CTLA4Ig treatment,
mice were intraperitoneally injected with 200 g of human CTLA4Ig
Chemotaxis Assays(Linsley et al., 1991) on days 0, 4, 7, and 10 and sacrificed on day 14.
Chemotaxis assays were performed as described (Seo et al., 2001)
using CXCL13/B lymphocyte chemoattractant (BLC) (R&D Systems,Flow Cytometry
Minneapolis, MN).0.5–1.5  106 cells were prepared and surface stained according
to standard protocols (Hardy et al., 1991). For B cell analysis, the
Statistical Analysisfollowing antibodies were purchased from BD PharMingen, San
Statistical significance was determined using an unpaired, two sam-Diego, CA: R11-153-biotin (anti-Ig1), RA3-6B2-biotin (anti-B220),
ple Student’s t test and Instat software.1D3-biotin (anti-CD19), and Cy34.1-FITC (anti-CD22). Polyclonal
rabbit anti-CXCR5 antiserum was a gift from J. Cyster (UCSF, San
AcknowledgmentsFrancisco, CA), and donkey anti-rabbit IgG-FITC was purchased
from Jackson ImmunoResearch Laboratories (West Grove, PA).
We thank Dr. Jason Cyster for the generous gift of BLR-1 antisera,187.1-FITC (anti-Ig) was grown as supernatant and conjugated.
Jeffrey Faust for cell sorting, and Kristin Hazard for outstandingJC5.1-PE (anti-Ig total) was a gift from J. Kearney (University of
technical assistance. This work was supported by grants from NIHAlabama, Birmingham), and streptavidin-Red670 was purchased
(AI32137, AR47913, AI24541), the Arthritis Foundation, and the How-from Gibco BRL, Gaithersburg, MD. Isotype control antibodies
ard Hughes Medical Institute (M.F.).showed no difference in staining between B cells in the different
strains/treatment groups of mice (data not shown).
Received: September 24, 2001For T cell analysis, 145-2C11-PE (anti-CD3) and H1.2F3-FITC (anti-
Revised: February 22, 2002CD69) were purchased from BD PharMingen. 53-6.72 (anti-CD8)
was purified from supernatant and biotinylated. In order to examine
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